Business
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB:...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingToronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce the formation of a multiple myeloma advisory board (\"MM Advisory Board\"). Driven by the success of TELO's recent clinical studies, announced on September 14, 2022, and as part of the Company's commercialization strategy, the Company has prioritized the formation of an internationally recognized clinical advisory board to help guide the development and commercial launch of its predictive and prognostic tests for multiple myeloma (\"MM\"). In addition to clinical product development, the MM Advisory Board will provide direction with regulatory strategies, clinical adoption, and the launch of its MM products. TELO is participating in the annual meeting of the American Society of Hematology (\"ASH\") 2022 taking place in New Orleans, USA, from December 10-13, 2022. TELO will hold its first MM Advisory Board meeting as an auxiliary event during ASH on December 13, 2022.The American Society of Hematology is a professional organization representing healthcare professionals involved in the management of blood disorders including blood cancers. The ASH annual meeting is considered the top clinical international meeting focused on blood cancers attracting more than 30,000 attendees every year, predominantly clinicians from all over the world.In addition to Dr. Richard Bender, the chair of the MM Advisory Board, announced on October 13, 2022, TELO has added four world-renowned key opinion leaders (\"KOLs\") who have contributed significantly to the advancement of MM disease management. The KOLs who have joined TELO's MM Advisory Board are Dr. Kenneth Anderson, MD; Dr. Shaji Kumar, MD; Dr. Elisabet Manasanch, MD; and Dr. James Berenson, MD.Dr. Kenneth Anderson is Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Harvard Medical School, as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. His paradigm for identifying and validating targets in tumor cells has transformed myeloma therapy and markedly improved patient o...